Acta Pharmaceutica最新文献_第10页

Ampelopsin induces MDA-MB-231 cell cycle arrest through cyclin B1-mediated PI3K/AKT/mTOR pathway in vitro and in vivo. 在体外和体内，蛇葡萄素通过细胞周期蛋白b1介导的PI3K/AKT/mTOR通路诱导MDA-MB-231细胞周期阻滞。

IF 2.8 4区医学

Acta Pharmaceutica Pub Date : 2023-03-01 DOI: 10.2478/acph-2023-0005

Minjun Meng, Qiaolu Yang, Zhong Ouyang, Qingmo Yang, Xinyi Wu, Yufan Huang, Yonghui Su, Shuanglong Chen, Wenlin Chen

{"title":"Ampelopsin induces MDA-MB-231 cell cycle arrest through cyclin B1-mediated PI3K/AKT/mTOR pathway in vitro and in vivo.","authors":"Minjun Meng, Qiaolu Yang, Zhong Ouyang, Qingmo Yang, Xinyi Wu, Yufan Huang, Yonghui Su, Shuanglong Chen, Wenlin Chen","doi":"10.2478/acph-2023-0005","DOIUrl":"https://doi.org/10.2478/acph-2023-0005","url":null,"abstract":"Breast cancer is one of the most common malignant tumors in women and it is the most frequently diagnosed cancer in the world. Ampelopsin (AMP) is a purified component from the root of Ampelopsis grossedentata. It is reported that AMP could significantly inhibit the proliferation of breast cancer cells. However, the antitumor mechanism against breast cancer has not yet been fully elucidated. The purpose of this work was to study the role of AMP against breast cancer MDA-MB-231 cells and to further investigate the underlying mechanism. PI3K/AKT/mTOR plays a very important role in tumor cell growth and proliferation and we hypothesize that AMP may inhibit this pathway. In the present work, the results showed that AMP could significantly inhibit the growth of breast cancer MDA-MB-231 cells in vitro and in vivo. In addition, treatment with AMP decreased the levels of PI3K, AKT and mTOR, as well as cyclin B1 expression, followed by p53/p21 pathway activation to arrest the cell cycle at G2/M. Moreover, it demonstrated a positive association between cyclin B1 and PI3K/AKT/mTOR levels. Importantly, this pathway was found to be regulated by cyclin B1 in MDA-MB-231 cells treated with AMP. Also, it was observed that cyclin B1 overexpression attenuated cell apoptosis and weakened the inhibitory effects of AMP on cell proliferation. Together, AMP could inhibit breast cancer MDA-MB-231 cell proliferation in vitro and in vivo, due to cell cycle arrest at G2/M by inactivating PI3K/AKT/mTOR pathway regulated by cyclin B1.","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 1","pages":"75-90"},"PeriodicalIF":2.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10609628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tablet characteristics and pharmacokinetics of orally disintegrating tablets containing coenzyme Q10 granules prepared by different methods. 不同方法制备辅酶Q10颗粒口腔崩解片的片剂特性及药动学研究

IF 2.8 4区医学

Acta Pharmaceutica Pub Date : 2023-03-01 DOI: 10.2478/acph-2023-0007

Yasuharu Kashiwagura, Shota Takusagawa, Yasuyuki Ikematsu, Shimako Tanaka, Noriyuki Namiki, Shinya Uchida

引用次数: 0

Effects of 3R, 16S-2-hydroxyethyl apovincaminate (HEAPO), donepezil and galantamine on learning and memory retention in naïve Wistar rats. 3R、16s -2-羟乙基载疫苗(HEAPO)、多奈哌齐和加兰他敏对naïve Wistar大鼠学习记忆保持的影响。

IF 2.8 4区医学

Acta Pharmaceutica Pub Date : 2023-03-01 DOI: 10.2478/acph-2023-0006

Darinka Dimitrova, Damianka Getova, Kremena Saracheva

引用次数: 0

Intensive critical care and management of asthmatic and smoker patients in COVID-19 infection. COVID-19感染哮喘和吸烟患者重症监护与管理

IF 2.8 4区医学

Acta Pharmaceutica Pub Date : 2023-03-01 DOI: 10.2478/acph-2023-0002

Dongming Lu, Obaid Yaqoob, Manish Kumar, Ajay Singh Kushwah, Rahul Kumar Sharma, Devinder Kumar, Yogendra Mavai, Rukaiya Khan

{"title":"Intensive critical care and management of asthmatic and smoker patients in COVID-19 infection.","authors":"Dongming Lu, Obaid Yaqoob, Manish Kumar, Ajay Singh Kushwah, Rahul Kumar Sharma, Devinder Kumar, Yogendra Mavai, Rukaiya Khan","doi":"10.2478/acph-2023-0002","DOIUrl":"https://doi.org/10.2478/acph-2023-0002","url":null,"abstract":"This century's most serious catastrophe, COVID-19, has been dubbed \"the most life-threatening disaster ever\". Asthmatic persons are even more prone to COVID-19's complex interplay with the underlying inflammatory condition. In order to protect themselves against COVID-19, asthmatic patients must be very vigilant in their usage of therapeutic techniques and drugs (e.g., bronchodilators, 5-lipoxygenase inhibitors), which may be accessed to deal with mild, moderate, and severe COVID-19 indications. People with asthma may have more severe COVID-19 symptoms, which may lead to a worsening of their condition. Several cytokines were found to be elevated in the bronchial tracts of patients with acute instances of COVID-19, suggesting that this ailment may aggravate asthma episodes by increasing inflammation. The intensity of COVID-19 symptoms is lessened in patients with asthma who have superior levels of T-cells. Several antibiotics, antivirals, antipyretics, and anti-inflammatory drugs have been suggested to suppress COVID-19 symptoms in asthmatic persons. Furthermore, smokers are more likely to have aggravated repercussions in COVID-19 infection. Being hospitalized to critical care due to COVID-19, needing mechanical breathing, and suffering from serious health repercussions, are all possible outcomes for someone who has previously smoked. Smoking damages airways and alveoli, which significantly raises the risk of COVID-19-related health complications. Patients with a previous record of smoking are predisposed to severe COVID-19 disease symptoms that essentially require a combination of bronchodilators, mucolytics, antivirals, and antimuscarinic drugs, to cope with the situation. The present review discusses the care and management of asthmatic and smoker patients in COVID-19 infection.","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 1","pages":"29-42"},"PeriodicalIF":2.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10609624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The opposite effect of convulsant drugs on neuronal and endothelial nitric oxide synthase - A possible explanation for the dual proconvulsive/anticonvulsive action of nitric oxide. 惊厥药物对神经元和内皮型一氧化氮合酶的相反作用——一氧化氮具有惊厥/抗惊厥双重作用的可能解释。

IF 2.8 4区医学

Acta Pharmaceutica Pub Date : 2023-03-01 DOI: 10.2478/acph-2023-0004

Lourdes A Vega Rasgado, Eva Ramón-Gallegos, Lorena Rodríguez-Páez, Verónica Alcántara-Farfán

{"title":"The opposite effect of convulsant drugs on neuronal and endothelial nitric oxide synthase - A possible explanation for the dual proconvulsive/anticonvulsive action of nitric oxide.","authors":"Lourdes A Vega Rasgado, Eva Ramón-Gallegos, Lorena Rodríguez-Páez, Verónica Alcántara-Farfán","doi":"10.2478/acph-2023-0004","DOIUrl":"https://doi.org/10.2478/acph-2023-0004","url":null,"abstract":"Nitric oxide (NO) participates in processes such as endothelium-dependent vasodilation and neurotransmission/neuromodulation. The role of NO in epilepsy is controversial, attributing it to anticonvulsant but also proconvulsant properties. Clarification of this dual effect of NO might lead to the development of new antiepileptic drugs. Previous results in our laboratory indicated that this contradictory role of NO in seizures could depend on the nitric oxide synthase (NOS) isoform involved, which could play opposite roles in epileptogenesis, one of them being proconvulsant but the other anticonvulsant. The effect of convulsant drugs on neuronal NO (nNO) and endothelial NO (eNO) levels was investigated. Considering the distribution of neuronal and endothelial NOS in neurons and astrocytes, resp., primary cultures of neurons and astrocytes were used as a study model. The effects of convulsant drugs pentylenetetrazole, thiosemicarbazide, 4-aminopyridine and bicuculline on NO levels were studied, using a spectrophotometric method. Their effects on NO levels in neurons and astrocytes depend on the concentration and time of treatment. These convulsant drugs caused an increase in nNO, but a decrease in eNO was proportional to the duration of treatment in both cases. Apparently, nNO possesses convulsant properties mediated by its effect on the glutamatergic and GABAergic systems, probably through GABAA receptors. Anticonvulsant properties of eNO may be the consequence of its effect on endothelial vasodilation and its capability to induce angiogenesis. Described effects last as seizures do. Considering the limitations of these kinds of studies and the unexplored influence of inducible NO, further investigations are required.","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 1","pages":"59-74"},"PeriodicalIF":2.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10609626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sodium butyrate attenuate hyperglycemia-induced inflammatory response and renal injury in diabetic mice. 丁酸钠减轻糖尿病小鼠高血糖诱导的炎症反应和肾损伤。

IF 2.8 4区医学

Acta Pharmaceutica Pub Date : 2023-03-01 DOI: 10.2478/acph-2023-0008

Man Yan, Yan-Yan Zhang, Yue Xi, Long-Kun Ding, Chang Sun, Li-Juan Qu, Xin Qian, Jing-Wen Xu, Wen Sun, Liang Wu

{"title":"Sodium butyrate attenuate hyperglycemia-induced inflammatory response and renal injury in diabetic mice.","authors":"Man Yan, Yan-Yan Zhang, Yue Xi, Long-Kun Ding, Chang Sun, Li-Juan Qu, Xin Qian, Jing-Wen Xu, Wen Sun, Liang Wu","doi":"10.2478/acph-2023-0008","DOIUrl":"https://doi.org/10.2478/acph-2023-0008","url":null,"abstract":"The activation of the monocyte-macrophage system and the damage to the renal and pancreatic tissue are common complications in patients with diabetes induced by hyper-glycemia. This study aimed to evaluate the effect and mechanism of butyrate (NaB), a metabolite of intestinal flora, on inhibiting the inflammatory response of human monocyte-macrophages (THP-1 cells) induced by high glucose and the damage of pancreatic and renal tissue in diabetic mice. The results showed that high concentration glucose significantly up-regulated the expressions of IL-1β, TNF-α, and NLRP3 in THP-1 cells and mouse spleen, and that NaB could inhibit the overexpression of those genes. The abundance of Beclin-1, LC3B and reactive oxygen species (ROS) in THP-1 cells is increased due to the high glucose concentration, and NaB can inhibit the genes responsible for upregulating the expression. In diabetic mice, vacuolar degeneration of renal tubules was observed. Then we observed that some of the epithelial cells of the renal tubules were exfoliated and some formed tubules. NaB could alleviate these pathological lesions, but NaB cannot alleviate pancreatic injury. Our results indicated that NaB could be used for the prevention and adjuvant treatment of diabetic kidney injury.","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 1","pages":"121-132"},"PeriodicalIF":2.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10609625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The in vitro anticancer effects of FS48 from salivary glands of Xenopsylla cheopis on NCI-H460 cells via its blockage of voltage-gated K⁺ channels. 非洲爪蟾唾液腺FS48通过阻断电压门控K+通道对NCI-H460细胞的体外抗癌作用

IF 2.8 4区医学

Acta Pharmaceutica Pub Date : 2023-03-01 DOI: 10.2478/acph-2023-0010

Weichen Xiong, Huizhen Fan, Qingye Zeng, Zhenhui Deng, Guanhui Li, Wancheng Lu, Bei Zhang, Shian Lai, Xin Chen, Xueqing Xu

{"title":"The in vitro anticancer effects of FS48 from salivary glands of Xenopsylla cheopis on NCI-H460 cells via its blockage of voltage-gated K+ channels.","authors":"Weichen Xiong, Huizhen Fan, Qingye Zeng, Zhenhui Deng, Guanhui Li, Wancheng Lu, Bei Zhang, Shian Lai, Xin Chen, Xueqing Xu","doi":"10.2478/acph-2023-0010","DOIUrl":"https://doi.org/10.2478/acph-2023-0010","url":null,"abstract":"Voltage-gated K+ (Kv) channels play a role in the cellular processes of various cancer cells, including lung cancer cells. We previously identified and reported a salivary protein from the Xenopsylla cheopis, FS48, which exhibited inhibitory activity against Kv1.1-1.3 channels when assayed in HEK 293T cells. However, whether FS48 has an inhibitory effect on cancer cells expressing Kv channels is unclear. The present study aims to reveal the effects of FS48 on the Kv channels and the NCI-H460 human lung cancer cells through patch clamp, MTT, wound healing, transwell, gelatinase zymography, qRT-PCR and WB assays. The results demonstrated that FS48 can be effective in suppressing the Kv currents, migration, and invasion of NCI-H460 cells in a dose-dependent manner, despite the failure to inhibit the proliferation. Moreover, the expression of Kv1.1 and Kv1.3 mRNA and protein were found to be significantly reduced. Finally, FS48 decreases the mRNA level of MMP-9 while increasing TIMP-1 mRNA level. The present study highlights for the first time that blood-sucking arthropod saliva-derived protein can inhibit the physiological activities of tumour cells via the Kv channels. Furthermore, FS48 can be taken as a hit compound against the tumour cells expressing Kv channels.","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 1","pages":"145-155"},"PeriodicalIF":2.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10609627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Recent approaches in the drug research and development of novel antimalarial drugs with new targets. 具有新靶点的新型抗疟药物研究和开发的最新途径。

IF 2.8 4区医学

Acta Pharmaceutica Pub Date : 2023-03-01 DOI: 10.2478/acph-2023-0001

Naveen Kumar Reddy Chinnappanna, Gopi Yennam, Chaitanya Budagam Haima Naga Venkata Chaitanya, Shinu Pottathil, Pobitra Borah, Katharigatta N Venugopala, Pran Kishore Deb, Raghu Prasad Mailavaram

{"title":"Recent approaches in the drug research and development of novel antimalarial drugs with new targets.","authors":"Naveen Kumar Reddy Chinnappanna, Gopi Yennam, Chaitanya Budagam Haima Naga Venkata Chaitanya, Shinu Pottathil, Pobitra Borah, Katharigatta N Venugopala, Pran Kishore Deb, Raghu Prasad Mailavaram","doi":"10.2478/acph-2023-0001","DOIUrl":"https://doi.org/10.2478/acph-2023-0001","url":null,"abstract":"Malaria is a serious worldwide medical issue that results in substantial annual death and morbidity. The availability of treatment alternatives is limited, and the rise of resistant parasite types has posed a significant challenge to malaria treatment. To prevent a public health disaster, novel antimalarial agents with single-dosage therapies, extensive curative capability, and new mechanisms are urgently needed. There are several approaches to developing antimalarial drugs, ranging from alterations of current drugs to the creation of new compounds with specific targeting abilities. The availability of multiple genomic techniques, as well as recent advancements in parasite biology, provides a varied collection of possible targets for the development of novel treatments. A number of promising pharmacological interference targets have been uncovered in modern times. As a result, our review concentrates on the most current scientific and technical progress in the innovation of new antimalarial medications. The protein kinases, choline transport inhibitors, dihydroorotate dehydrogenase inhibitors, isoprenoid biosynthesis inhibitors, and enzymes involved in the metabolism of lipids and replication of deoxyribonucleic acid, are among the most fascinating antimalarial target proteins presently being investigated. The new cellular targets and drugs which can inhibit malaria and their development techniques are summarised in this study.","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 1","pages":"1-27"},"PeriodicalIF":2.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10619429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Effects of tranquilization therapy in elderly patients suffering from chronic non-communicable diseases: A meta-analysis. 镇静治疗对老年慢性非传染性疾病患者的影响:一项荟萃分析

IF 2.8 4区医学

Acta Pharmaceutica Pub Date : 2023-03-01 DOI: 10.2478/acph-2023-0003

Jing Li, Jing Li, Yulan Cui, Honggeng Li, Xiaoxuan Hou, Fang Zhao, Qing Zhao, Junlan Zhao, Pengchao Lin

{"title":"Effects of tranquilization therapy in elderly patients suffering from chronic non-communicable diseases: A meta-analysis.","authors":"Jing Li, Jing Li, Yulan Cui, Honggeng Li, Xiaoxuan Hou, Fang Zhao, Qing Zhao, Junlan Zhao, Pengchao Lin","doi":"10.2478/acph-2023-0003","DOIUrl":"https://doi.org/10.2478/acph-2023-0003","url":null,"abstract":"The current meta-analysis searched the literature connected to different tranquilizers used to treat elderly people and assessed it in terms of dose, types of outcomes and adverse effects, to determine a safe and acceptable tranquilizer and its optimal dose. A systematic literature review was undertaken for randomized controlled trials, case-control, retrospective and prospective studies on the use of tranquilizers in elderly patients, using PubMed, Ebsco, SCOPUS and Web of Science. PICOS criteria were used to select studies, and pertinent event data was collected. This meta-analysis includes 16 randomized control trials spanning the years 2000 to 2022, using the data from 2224 patients. The trials that were included used various tranquilizers such as diazepam, alprazolam, temazepam and lorazepam, and indicated high treatment efficacy and low adverse effects. With a p-value of 0.853 for Egger's test and 0.13 for Begg's test, the current meta-analysis shows a minimal probability of publication bias. A recent meta-analysis supports the use of tranquilizers in older people to treat sleeplessness, epilepsy or anxiety, but only at modest doses, because large doses are harmful and produce numerous withdrawal symptoms.","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 1","pages":"43-57"},"PeriodicalIF":2.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9193835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vitro effects of ascorbic acid on viability and metabolism of patients' osteosarcoma stem cells. 体外抗坏血酸对骨肉瘤干细胞活力和代谢的影响。

IF 2.8 4区医学

Acta Pharmaceutica Pub Date : 2022-12-01 DOI: 10.2478/acph-2022-0040

Marijana Šimić Jovičić, Maja Pušić, Maja Antunović, Maja Ledinski, Lucija Librenjak, Robert Kolundžić, Tomislav Ribičić, Vladimir Trkulja, Inga Urlić

{"title":"In vitro effects of ascorbic acid on viability and metabolism of patients' osteosarcoma stem cells.","authors":"Marijana Šimić Jovičić, Maja Pušić, Maja Antunović, Maja Ledinski, Lucija Librenjak, Robert Kolundžić, Tomislav Ribičić, Vladimir Trkulja, Inga Urlić","doi":"10.2478/acph-2022-0040","DOIUrl":"https://doi.org/10.2478/acph-2022-0040","url":null,"abstract":"Stagnation in novelties of osteosarcoma (OS) treatment indicates the need for new therapeutic methods. OS cancer stem cells (OS-CSC) are taught to have the ability to self-renew and develop mechanisms of anticancer drug resistance, and this is why it is difficult to eradicate them. Their metabolism has been recognized as a potential target of therapeutic action. Ascorbic acid (AA) is considered to act pro-oxidative against OS-CSC in vitro by oxidative effect and by inhibition of glycolysis. This study examined an in vitro impact of AA on OS-CSC metabolism isolated from patients' biopsies, with the aim of better understanding of OS-CSC metabolism and the action of AA on OS-CSC. OS-CSC were isolated using a sphere culture system and identified as stem cells using Hoechst 33342 exclusion assay. Determination of the dominant type of metabolism of OS-CSC, parental OS cells, human mesenchymal stem cells (hMSC) and U2OS OS lineage before and after AA treatment was done by Seahorse XF (Agilent). Cytotoxicity of high-dose AA was confirmed by the MTT test and was proven for all the examined cell types as well as HEK293. Seahorse technology showed that OS-CSC can potentially use both glycolysis and oxidative phosphorylation (OXPHOS), and can turn to glycolysis and slow metabolic potential in unfavorable conditions such as incubation in AA.","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"72 4","pages":"599-613"},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9600792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0